{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:47:24Z","timestamp":1784562444691,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHS-N-260-2005-00007-C"],"award-info":[{"award-number":["HHS-N-260-2005-00007-C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["N01-EY-5-0007"],"award-info":[{"award-number":["N01-EY-5-0007"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["CTA-00833"],"award-info":[{"award-number":["CTA-00833"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.oret.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:19:11Z","timestamp":1547198351000},"page":"326-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4"],"prefix":"10.1016","volume":"3","author":[{"given":"Amitha","family":"Domalpally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan B.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Elman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-9802","authenticated-orcid":false,"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2019.01.004_bib1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch. Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ophtha.2014.12.007","article-title":"Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic whites with diabetic macular edema in the United States","volume":"122","author":"Varma","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","article-title":"UK AMD EMR Users Group Report V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12","volume":"99","author":"Lee","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2019.01.004_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib7","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2019.01.004_bib8","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with two-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib11","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ajo.2015.07.034","article-title":"Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration","volume":"160","author":"Regillo","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamaophthalmol.2016.5314","article-title":"The potential importance of detection of neovascular age-related macular degeneration when visual acuity is relatively good","volume":"135","author":"Ho","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/OPTH.S59012","article-title":"Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration","volume":"9","author":"Keane","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","article-title":"Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the eye (HOME) study","volume":"121","author":"Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cct.2014.02.003","article-title":"Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design\u2014HOME Study report number 1","volume":"37","author":"Chew","year":"2014","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.oret.2019.01.004_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/IAE.0000000000000940","article-title":"Effectiveness of different monitoring modalities in the detection of neovascular age-related macular degeneration: The HOME Study.report number 3","volume":"36","author":"Chew","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2019.01.004_bib17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report No. 17","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2019.01.004_bib18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib19","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2019.01.004_bib20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/eye.2015.44","article-title":"The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography","volume":"29","author":"Wilde","year":"2015","journal-title":"Eye"},{"key":"10.1016\/j.oret.2019.01.004_bib21","article-title":"Optical coherence tomography, fluorescein angiography, and diagnosis of\u00a0choroidal neovascularization in age-related macular degeneration","author":"Gualino","year":"2018","journal-title":"Retina"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018305840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018305840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:43Z","timestamp":1762853143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018305840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2468653018305840"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2019.01.004","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}